Form 8-K - Current report:
SEC Accession No. 0001104659-25-087465
Filing Date
2025-09-04
Accepted
2025-09-04 16:05:41
Documents
13
Period of Report
2025-08-29
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2525057d1_8k.htm   iXBRL 8-K 52701
2 EXHIBIT 10.1 tm2525057d1_ex10-1.htm EX-10.1 9540
  Complete submission text file 0001104659-25-087465.txt   233638

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA syn-20250829.xsd EX-101.SCH 3041
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE syn-20250829_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syn-20250829_pre.xml EX-101.PRE 22377
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2525057d1_8k_htm.xml XML 3692
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

EIN.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12584 | Film No.: 251293401
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)